Biomarker Application for Precision Medicine in Stroke

Alexis N. Simpkins; Miroslaw Janowski; Helieh S. Oz; Jill Roberts; Gregory Bix; Sylvain Doré; Ann M. Stowe

doi:10.1007/s12975-019-00762-3

Biomarker Application for Precision Medicine in Stroke

Alexis N. Simpkins, Miroslaw Janowski, Helieh S. Oz, Jill Roberts, Gregory Bix, Sylvain Doré, Ann M. Stowe

Research output: Contribution to journal › Review article › peer-review

62 Scopus citations

Abstract

Stroke remains one of the leading causes of long-term disability and mortality despite recent advances in acute thrombolytic therapies. In fact, the global lifetime risk of stroke in adults over the age of 25 is approximately 25%, with 24.9 million cases of ischemic stroke and 18.7 million cases of hemorrhagic stroke reported in 2015. One of the main challenges in developing effective new acute therapeutics and enhanced long-term interventions for stroke recovery is the heterogeneity of stroke, including etiology, comorbidities, and lifestyle factors that uniquely affect each individual stroke survivor. In this comprehensive review, we propose that future biomarker studies can be designed to support precision medicine therapeutic interventions after stroke. The current challenges in defining ideal biomarkers for stroke are highlighted, including consideration of disease course, age, lifestyle factors, and subtypes of stroke. This overview of current clinical trials includes biomarker collection, and concludes with an example of biomarker design for aneurysmal subarachnoid hemorrhage. With the advent of “-omics” studies, neuroimaging, big data, and precision medicine, well-designed stroke biomarker trials will greatly advance the treatment of a disease that affects millions globally every year.

Original language	English
Pages (from-to)	615-627
Number of pages	13
Journal	Translational Stroke Research
Volume	11
Issue number	4
DOIs	https://doi.org/10.1007/s12975-019-00762-3
State	Published - Aug 1 2020

Bibliographical note

Publisher Copyright:
© 2019, The Author(s).

Funding

We would like to thank Dr. Tony Parker, Queensland University of Technology, plus the organizers and attendees of the University of Kentucky’s STRAW (Stroke Translational Research Advancement Workshop) for contribution to initial discussions held on October 24 and 25, 2018, in Lexington, KY, USA. This effort was also partially supportedby grants from the National Institutes of Health (R21NS095166 (SD), R01NS091100 (MJ)) and the American Heart Association (17GRNT33450010 (SD), 19EIA34760279 (AMS)).

Funders	Funder number
National Institutes of Health (NIH)	R01NS091100
National Institute of Neurological Disorders and Stroke	R21NS095166
American Heart Association	AMS, 19EIA34760279, 17GRNT33450010
University of Kentucky
Queensland University of Technology QUT

Keywords

'omics'
big data
biomarker
clinical trials
hemorrhagic stroke
ischemic stroke
precision medicine

ASJC Scopus subject areas

General Neuroscience
Clinical Neurology
Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s12975-019-00762-3

Cite this

@article{c15220f132d74c0a8e9db6fd9d632081,

title = "Biomarker Application for Precision Medicine in Stroke",

abstract = "Stroke remains one of the leading causes of long-term disability and mortality despite recent advances in acute thrombolytic therapies. In fact, the global lifetime risk of stroke in adults over the age of 25 is approximately 25%, with 24.9 million cases of ischemic stroke and 18.7 million cases of hemorrhagic stroke reported in 2015. One of the main challenges in developing effective new acute therapeutics and enhanced long-term interventions for stroke recovery is the heterogeneity of stroke, including etiology, comorbidities, and lifestyle factors that uniquely affect each individual stroke survivor. In this comprehensive review, we propose that future biomarker studies can be designed to support precision medicine therapeutic interventions after stroke. The current challenges in defining ideal biomarkers for stroke are highlighted, including consideration of disease course, age, lifestyle factors, and subtypes of stroke. This overview of current clinical trials includes biomarker collection, and concludes with an example of biomarker design for aneurysmal subarachnoid hemorrhage. With the advent of “-omics” studies, neuroimaging, big data, and precision medicine, well-designed stroke biomarker trials will greatly advance the treatment of a disease that affects millions globally every year.",

keywords = "'omics', big data, biomarker, clinical trials, hemorrhagic stroke, ischemic stroke, precision medicine",

author = "Simpkins, {Alexis N.} and Miroslaw Janowski and Oz, {Helieh S.} and Jill Roberts and Gregory Bix and Sylvain Dor{\'e} and Stowe, {Ann M.}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2020",

month = aug,

day = "1",

doi = "10.1007/s12975-019-00762-3",

language = "English",

volume = "11",

pages = "615--627",

number = "4",

}

TY - JOUR

T1 - Biomarker Application for Precision Medicine in Stroke

AU - Simpkins, Alexis N.

AU - Janowski, Miroslaw

AU - Oz, Helieh S.

AU - Roberts, Jill

AU - Bix, Gregory

AU - Doré, Sylvain

AU - Stowe, Ann M.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Stroke remains one of the leading causes of long-term disability and mortality despite recent advances in acute thrombolytic therapies. In fact, the global lifetime risk of stroke in adults over the age of 25 is approximately 25%, with 24.9 million cases of ischemic stroke and 18.7 million cases of hemorrhagic stroke reported in 2015. One of the main challenges in developing effective new acute therapeutics and enhanced long-term interventions for stroke recovery is the heterogeneity of stroke, including etiology, comorbidities, and lifestyle factors that uniquely affect each individual stroke survivor. In this comprehensive review, we propose that future biomarker studies can be designed to support precision medicine therapeutic interventions after stroke. The current challenges in defining ideal biomarkers for stroke are highlighted, including consideration of disease course, age, lifestyle factors, and subtypes of stroke. This overview of current clinical trials includes biomarker collection, and concludes with an example of biomarker design for aneurysmal subarachnoid hemorrhage. With the advent of “-omics” studies, neuroimaging, big data, and precision medicine, well-designed stroke biomarker trials will greatly advance the treatment of a disease that affects millions globally every year.

AB - Stroke remains one of the leading causes of long-term disability and mortality despite recent advances in acute thrombolytic therapies. In fact, the global lifetime risk of stroke in adults over the age of 25 is approximately 25%, with 24.9 million cases of ischemic stroke and 18.7 million cases of hemorrhagic stroke reported in 2015. One of the main challenges in developing effective new acute therapeutics and enhanced long-term interventions for stroke recovery is the heterogeneity of stroke, including etiology, comorbidities, and lifestyle factors that uniquely affect each individual stroke survivor. In this comprehensive review, we propose that future biomarker studies can be designed to support precision medicine therapeutic interventions after stroke. The current challenges in defining ideal biomarkers for stroke are highlighted, including consideration of disease course, age, lifestyle factors, and subtypes of stroke. This overview of current clinical trials includes biomarker collection, and concludes with an example of biomarker design for aneurysmal subarachnoid hemorrhage. With the advent of “-omics” studies, neuroimaging, big data, and precision medicine, well-designed stroke biomarker trials will greatly advance the treatment of a disease that affects millions globally every year.

KW - 'omics'

KW - big data

KW - biomarker

KW - clinical trials

KW - hemorrhagic stroke

KW - ischemic stroke

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85076895815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076895815&partnerID=8YFLogxK

U2 - 10.1007/s12975-019-00762-3

DO - 10.1007/s12975-019-00762-3

M3 - Review article

C2 - 31848851

AN - SCOPUS:85076895815

SN - 1868-4483

VL - 11

SP - 615

EP - 627

JO - Translational Stroke Research

JF - Translational Stroke Research

IS - 4

ER -

Biomarker Application for Precision Medicine in Stroke

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this